Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure
Tamara B. Horwich, MD*,
W. Robb MacLellan, MD, FACC* and
Gregg C. Fonarow, MD, FACC*,*
* Ahmanson-UCLA Cardiomyopathy Center, Los Angeles, California, USA
View larger version (14K):
[in a new window]
|
Figure 1 Kaplan-Meier curves demonstrate one-year survival (%) without the need for urgent heart transplantation in cohorts of non-ischemic (n = 298) and ischemic (n = 244) heart failure patients. Rx = therapy.
|
|
View larger version (17K):
[in a new window]
|
Figure 2 One-year hazard ratios (HRs) and 95% confidence intervals (CIs) for death or urgent transplantation, death from any cause, progressive heart failure death, and sudden death for patients receiving statins compared with those not receiving statins.
|
|
View larger version (19K):
[in a new window]
|
Figure 3 Two-year rates of death or urgent transplantation in statin versus no-statin cohorts. The benefit associated with statin therapy in the total cohort was compared with subgroups of men and women, those with cholesterol above and below the median level (163 mg/dl), and a subgroup excluding patients who underwent elective or urgent transplantation. HR = hazard ratio with statin therapy (Rx); TC = total cholesterol.
|
|
|
